Synthetic Biology News and Research

RSS

Synthetic biologists develop versatile platform for targeted drug delivery

In recent years, cell and gene therapies have shown significant promise for treating cancer, cystic fibrosis, diabetes, heart disease, HIV/AIDS and other difficult-to-treat diseases.

27 Nov 2023

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy.

From NanoSyrinx 13 Nov 2023

New device could keep implantable "living pharmacy" cells alive for months

In 2021, a Northwestern University-led research team received a Defense Advanced Research Projects Agency (DARPA) contract worth up to $33 million to develop an implantable "living pharmacy" to control the human body's sleep/wake cycles.

9 Nov 2023

Science, Innovation, and Xenotransplantation: A Discussion with Dr. Wenning Qin

In this interview, we delve deep into the pioneering world of xenotransplantation and the evolving landscape of gene editing.

2 Nov 2023

Using synthetic biology to develop smarter cell therapies for cancer patients

We are embarking on an unprecedented era of therapeutic development enabled by live cell engineering.

31 Oct 2023

Evonetix places first DNA synthesis development platform at Imperial College London

External placement marks a key milestone in the development of Evonetix’s benchtop DNA synthesis technology in preparation for customer use and commercialization.

From Evonetix 4 Oct 2023

Sphere Fluidics’ Cyto-Mine system selected by FairJourney Biologics to advance cell line development workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world leading end-to-end antibody partner, providing integrated services across antibody discovery, engineering, and production, to expand its cell line development capabilities.

From Fluidic Sciences and Sphere Bio 4 Oct 2023

$45M awarded to develop sense-and-respond implant technology for cancer treatment

The Advanced Research Projects Agency for Health (ARPA-H) has awarded $45 million to rapidly develop sense-and-respond implant technology that could slash U.S. cancer-related deaths by more than 50%.

26 Sep 2023

Future-proof vaccine candidate protects against wide range of coronaviruses

Studies of a 'future-proof' vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in animals.

25 Sep 2023

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

From LabGenius 19 Sep 2023

Innovative technique provides unparalleled insight into autism pathology

Does the human brain have an Achilles heel that ultimately leads to Autism? With a revolutionizing novel system that combines brain organoid technology and intricate genetics, researchers can now comprehensively test the effect of multiple mutations in parallel and at a single-cell level within human brain organoids.

13 Sep 2023

Bacteria ship cellular cargo by "surfing" along proteins, study finds

Bacteria live in nearly every habitat on earth including within soil, water, acidic hot springs and even within our own guts.

22 Aug 2023

Unleashing the Power of Microfluidic Picodroplets

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Richard Hammond, Chief Technical Officer at Sphere Bio, about their microfluidic picodroplet technology and more.

From Fluidic Sciences and Sphere Bio 21 Aug 2023

Researchers design a probiotic to suppress autoimmunity in the brain

Brigham researchers are working on a new approach to target autoimmunity in the brain leverages designer bacteria to make treatment safer and more effective.

9 Aug 2023

New protein-based nano-switches could lead to faster, more accurate diagnostic tests

QUT researchers have developed a new approach for designing molecular ON-OFF switches based on proteins which can be used in a multitude of biotechnological, biomedical and bioengineering applications.

27 Jul 2023

Arming phages with heterologous effectors paves the way for successful UTI treatment

Study demonstrated how phage can be engineered to produce bacteriocins and cell wall hydrolases as antimicrobial effector genes.

24 Jul 2023

AI and infection control: preventing infectious disease outbreaks and pandemics

Researchers discussed the role of artificial intelligence (AI) in preventing outbreaks of infectious diseases and future pandemics.

19 Jul 2023

Scientists develop breakthrough approach to create artificial allosteric sites in protein complexes

According to a recently published research paper by a team of scientists, a groundbreaking approach has been developed to create artificial allosteric sites (where by binding an effector molecule, activity at the distal active site is regulated) in protein complexes.

6 Jul 2023

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA.

From Fluidic Sciences and Sphere Bio 6 Jul 2023

Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries.

From Camena Bioscience 3 Jul 2023